Regeneron (NASDAQ: REGN) has been one of the better-performing biotech giants in the past year, with the company's shares rising by 33% in the past 12 months compared to the S&P 500's gains of about 9%. No doubt the drugmaker owes this performance in part to its coronavirus-related work. However, Regeneron is now facing severe headwinds in this market (more on that below).
Should investors still bet on this healthcare giant to continue outperforming the market?
Source Fool.com